Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and... by Yakun Wang, Jifang Gong, Airong Wang, Jia Wei, Zhi Peng, Xicheng Wang, Jun Zhou, Changsong Qi, Dan Liu, Jian Li, Ming Lu, Zhihao Lu, Yanshuo Cao, Jiajia Yuan, Ruyan Zhang, Jianmin Fang, Xiaotian Zhang, Lin Shen

“…The findings of our phase 1 clinical trial support further investigation of HER2-targeted ADC plus immunotherapy in HER2-expressing G/GEJ cancer and pancancer treatment in the future. Funding: Beijing Municipal Medical Research Institutes, Beijing Medical Research Institute (Z200015).…”
Get full text

Digital adaptation of the Standing up for Myself intervention in young people and adults with intellectual disabilities: the STORM feasibility study by Katrina Scior, Lisa Richardson, Elizabeth Randell, Michaela Osborne, Harriet Bird, Afia Ali, Eva-Maria Bonin, Adrian Brown, Celia Brown, Christine-Koulla Burke, Lisa Bush, Jason Crabtree, Karuna Davies, Paul Davies, David Gillespie, Andrew Jahoda, Sean Johnson, Richard Hastings, Laura Kerr, Rachel McNamara, Jane Menzies, Harry Roche, Melissa Wright, Kyann Zhang

“…They reviewed findings from the pilot against the progression criteria and made recommendations to the National Institute for Health and Care Research (NIHR) regarding the potential for a future funding application. Inclusion and exclusion criteria Groups from third and education sector organisations were included where they had a willing facilitator and organisational support in place, were meeting or restarting meetings as a group for at least 3 further months and were willing to replace five of their meetings with Digital STORM. …”
Get full text